 | • レポートコード：QYR2104Z3995 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、骨髄線維症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（輸血、化学療法、アンドロゲン療法）、用途別市場規模（病院、診療所、骨髄移植センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・骨髄線維症治療の市場動向 ・企業の競争状況、市場シェア ・骨髄線維症治療の種類別市場規模（輸血、化学療法、アンドロゲン療法） ・骨髄線維症治療の用途別市場規模（病院、診療所、骨髄移植センター） ・骨髄線維症治療の北米市場規模2016-2027（アメリカ、カナダ） ・骨髄線維症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・骨髄線維症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・骨髄線維症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・骨髄線維症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Incyte、Novartis、Celgene、Mylan Pharmaceuticals、Bristol-Myers Squibb、Eli Lilly、Taro Pharmaceuticals、AllCells、Lonza Group、ATCC） ・結論 |
Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.
On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.
Market Analysis and Insights: Global Myelofibrosis Treatment Market
The global Myelofibrosis Treatment market size is projected to reach US$ 750 million by 2026, from US$ 575.4 million in 2019, at a CAGR of 3.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myelofibrosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myelofibrosis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myelofibrosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myelofibrosis Treatment market.
Global Myelofibrosis Treatment Scope and Market Size
Myelofibrosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myelofibrosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Blood Transfusion
Chemotherapy
Androgen Therapy
Segment by Application
Hospitals
Clinics
Bone Marrow Transplant Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Incyte
Novartis
Celgene
Mylan Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Taro Pharmaceuticals
AllCells
Lonza Group
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelofibrosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Blood Transfusion
1.2.3 Chemotherapy
1.2.4 Androgen Therapy
1.3 Market by Application
1.3.1 Global Myelofibrosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Bone Marrow Transplant Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myelofibrosis Treatment Market Perspective (2016-2027)
2.2 Myelofibrosis Treatment Growth Trends by Regions
2.2.1 Myelofibrosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myelofibrosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Myelofibrosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Myelofibrosis Treatment Industry Dynamic
2.3.1 Myelofibrosis Treatment Market Trends
2.3.2 Myelofibrosis Treatment Market Drivers
2.3.3 Myelofibrosis Treatment Market Challenges
2.3.4 Myelofibrosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelofibrosis Treatment Players by Revenue
3.1.1 Global Top Myelofibrosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Myelofibrosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Myelofibrosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myelofibrosis Treatment Revenue
3.4 Global Myelofibrosis Treatment Market Concentration Ratio
3.4.1 Global Myelofibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelofibrosis Treatment Revenue in 2020
3.5 Myelofibrosis Treatment Key Players Head office and Area Served
3.6 Key Players Myelofibrosis Treatment Product Solution and Service
3.7 Date of Enter into Myelofibrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelofibrosis Treatment Breakdown Data by Type
4.1 Global Myelofibrosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Myelofibrosis Treatment Forecasted Market Size by Type (2022-2027)
5 Myelofibrosis Treatment Breakdown Data by Application
5.1 Global Myelofibrosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Myelofibrosis Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Myelofibrosis Treatment Market Size (2016-2027)
6.2 North America Myelofibrosis Treatment Market Size by Type
6.2.1 North America Myelofibrosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Myelofibrosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Myelofibrosis Treatment Market Size by Type (2016-2027)
6.3 North America Myelofibrosis Treatment Market Size by Application
6.3.1 North America Myelofibrosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Myelofibrosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Myelofibrosis Treatment Market Size by Application (2016-2027)
6.4 North America Myelofibrosis Treatment Market Size by Country
6.4.1 North America Myelofibrosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Myelofibrosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Myelofibrosis Treatment Market Size (2016-2027)
7.2 Europe Myelofibrosis Treatment Market Size by Type
7.2.1 Europe Myelofibrosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Myelofibrosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Myelofibrosis Treatment Market Size by Type (2016-2027)
7.3 Europe Myelofibrosis Treatment Market Size by Application
7.3.1 Europe Myelofibrosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Myelofibrosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Myelofibrosis Treatment Market Size by Application (2016-2027)
7.4 Europe Myelofibrosis Treatment Market Size by Country
7.4.1 Europe Myelofibrosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Myelofibrosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Myelofibrosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Myelofibrosis Treatment Market Size by Type
8.2.1 Asia-Pacific Myelofibrosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myelofibrosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myelofibrosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Myelofibrosis Treatment Market Size by Application
8.3.1 Asia-Pacific Myelofibrosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myelofibrosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myelofibrosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Myelofibrosis Treatment Market Size by Region
8.4.1 Asia-Pacific Myelofibrosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myelofibrosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Myelofibrosis Treatment Market Size (2016-2027)
9.2 Latin America Myelofibrosis Treatment Market Size by Type
9.2.1 Latin America Myelofibrosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Myelofibrosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Myelofibrosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Myelofibrosis Treatment Market Size by Application
9.3.1 Latin America Myelofibrosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Myelofibrosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Myelofibrosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Myelofibrosis Treatment Market Size by Country
9.4.1 Latin America Myelofibrosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Myelofibrosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelofibrosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Myelofibrosis Treatment Market Size by Type
10.2.1 Middle East & Africa Myelofibrosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myelofibrosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myelofibrosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Myelofibrosis Treatment Market Size by Application
10.3.1 Middle East & Africa Myelofibrosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myelofibrosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myelofibrosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Myelofibrosis Treatment Market Size by Country
10.4.1 Middle East & Africa Myelofibrosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myelofibrosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Incyte
11.1.1 Incyte Company Details
11.1.2 Incyte Business Overview
11.1.3 Incyte Myelofibrosis Treatment Introduction
11.1.4 Incyte Revenue in Myelofibrosis Treatment Business (2016-2021)
11.1.5 Incyte Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Myelofibrosis Treatment Introduction
11.2.4 Novartis Revenue in Myelofibrosis Treatment Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Celgene
11.3.1 Celgene Company Details
11.3.2 Celgene Business Overview
11.3.3 Celgene Myelofibrosis Treatment Introduction
11.3.4 Celgene Revenue in Myelofibrosis Treatment Business (2016-2021)
11.3.5 Celgene Recent Development
11.4 Mylan Pharmaceuticals
11.4.1 Mylan Pharmaceuticals Company Details
11.4.2 Mylan Pharmaceuticals Business Overview
11.4.3 Mylan Pharmaceuticals Myelofibrosis Treatment Introduction
11.4.4 Mylan Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2016-2021)
11.4.5 Mylan Pharmaceuticals Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Myelofibrosis Treatment Introduction
11.5.4 Bristol-Myers Squibb Revenue in Myelofibrosis Treatment Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Myelofibrosis Treatment Introduction
11.6.4 Eli Lilly Revenue in Myelofibrosis Treatment Business (2016-2021)
11.6.5 Eli Lilly Recent Development
11.7 Taro Pharmaceuticals
11.7.1 Taro Pharmaceuticals Company Details
11.7.2 Taro Pharmaceuticals Business Overview
11.7.3 Taro Pharmaceuticals Myelofibrosis Treatment Introduction
11.7.4 Taro Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2016-2021)
11.7.5 Taro Pharmaceuticals Recent Development
11.8 AllCells
11.8.1 AllCells Company Details
11.8.2 AllCells Business Overview
11.8.3 AllCells Myelofibrosis Treatment Introduction
11.8.4 AllCells Revenue in Myelofibrosis Treatment Business (2016-2021)
11.8.5 AllCells Recent Development
11.9 Lonza Group
11.9.1 Lonza Group Company Details
11.9.2 Lonza Group Business Overview
11.9.3 Lonza Group Myelofibrosis Treatment Introduction
11.9.4 Lonza Group Revenue in Myelofibrosis Treatment Business (2016-2021)
11.9.5 Lonza Group Recent Development
11.10 ATCC
11.10.1 ATCC Company Details
11.10.2 ATCC Business Overview
11.10.3 ATCC Myelofibrosis Treatment Introduction
11.10.4 ATCC Revenue in Myelofibrosis Treatment Business (2016-2021)
11.10.5 ATCC Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Myelofibrosis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Blood Transfusion
Table 3. Key Players of Chemotherapy
Table 4. Key Players of Androgen Therapy
Table 5. Global Myelofibrosis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Myelofibrosis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myelofibrosis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Myelofibrosis Treatment Market Share by Regions (2016-2021)
Table 9. Global Myelofibrosis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Myelofibrosis Treatment Market Share by Regions (2022-2027)
Table 11. Myelofibrosis Treatment Market Trends
Table 12. Myelofibrosis Treatment Market Drivers
Table 13. Myelofibrosis Treatment Market Challenges
Table 14. Myelofibrosis Treatment Market Restraints
Table 15. Global Myelofibrosis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Myelofibrosis Treatment Market Share by Players (2016-2021)
Table 17. Global Top Myelofibrosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelofibrosis Treatment as of 2020)
Table 18. Ranking of Global Top Myelofibrosis Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Myelofibrosis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Myelofibrosis Treatment Product Solution and Service
Table 22. Date of Enter into Myelofibrosis Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Myelofibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Myelofibrosis Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Myelofibrosis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Myelofibrosis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Myelofibrosis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Myelofibrosis Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Myelofibrosis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Myelofibrosis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Myelofibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Myelofibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Myelofibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Myelofibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Myelofibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Myelofibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Myelofibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Myelofibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Myelofibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Myelofibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Myelofibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Myelofibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Myelofibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Myelofibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Myelofibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Myelofibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Myelofibrosis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Myelofibrosis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Myelofibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Myelofibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Myelofibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Myelofibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Myelofibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Myelofibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Myelofibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Myelofibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Myelofibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Myelofibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Myelofibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Myelofibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Incyte Company Details
Table 63. Incyte Business Overview
Table 64. Incyte Myelofibrosis Treatment Product
Table 65. Incyte Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 66. Incyte Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Myelofibrosis Treatment Product
Table 70. Novartis Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. Celgene Company Details
Table 73. Celgene Business Overview
Table 74. Celgene Myelofibrosis Treatment Product
Table 75. Celgene Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 76. Celgene Recent Development
Table 77. Mylan Pharmaceuticals Company Details
Table 78. Mylan Pharmaceuticals Business Overview
Table 79. Mylan Pharmaceuticals Myelofibrosis Treatment Product
Table 80. Mylan Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 81. Mylan Pharmaceuticals Recent Development
Table 82. Bristol-Myers Squibb Company Details
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Myelofibrosis Treatment Product
Table 85. Bristol-Myers Squibb Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 86. Bristol-Myers Squibb Recent Development
Table 87. Eli Lilly Company Details
Table 88. Eli Lilly Business Overview
Table 89. Eli Lilly Myelofibrosis Treatment Product
Table 90. Eli Lilly Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 91. Eli Lilly Recent Development
Table 92. Taro Pharmaceuticals Company Details
Table 93. Taro Pharmaceuticals Business Overview
Table 94. Taro Pharmaceuticals Myelofibrosis Treatment Product
Table 95. Taro Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 96. Taro Pharmaceuticals Recent Development
Table 97. AllCells Company Details
Table 98. AllCells Business Overview
Table 99. AllCells Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 100. AllCells Recent Development
Table 101. Lonza Group Company Details
Table 102. Lonza Group Business Overview
Table 103. Lonza Group Myelofibrosis Treatment Product
Table 104. Lonza Group Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 105. Lonza Group Recent Development
Table 106. ATCC Company Details
Table 107. ATCC Business Overview
Table 108. ATCC Myelofibrosis Treatment Product
Table 109. ATCC Revenue in Myelofibrosis Treatment Business (2016-2021) & (US$ Million)
Table 110. ATCC Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelofibrosis Treatment Market Share by Type: 2020 VS 2027
Figure 2. Blood Transfusion Features
Figure 3. Chemotherapy Features
Figure 4. Androgen Therapy Features
Figure 5. Global Myelofibrosis Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Bone Marrow Transplant Centers Case Studies
Figure 9. Myelofibrosis Treatment Report Years Considered
Figure 10. Global Myelofibrosis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Myelofibrosis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Myelofibrosis Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Myelofibrosis Treatment Market Share by Regions (2022-2027)
Figure 14. Global Myelofibrosis Treatment Market Share by Players in 2020
Figure 15. Global Top Myelofibrosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelofibrosis Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Myelofibrosis Treatment Revenue in 2020
Figure 17. Global Myelofibrosis Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Myelofibrosis Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Myelofibrosis Treatment Market Share by Type (2016-2027)
Figure 21. North America Myelofibrosis Treatment Market Share by Application (2016-2027)
Figure 22. North America Myelofibrosis Treatment Market Share by Country (2016-2027)
Figure 23. United States Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myelofibrosis Treatment Market Share by Type (2016-2027)
Figure 27. Europe Myelofibrosis Treatment Market Share by Application (2016-2027)
Figure 28. Europe Myelofibrosis Treatment Market Share by Country (2016-2027)
Figure 29. Germany Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myelofibrosis Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Myelofibrosis Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Myelofibrosis Treatment Market Share by Region (2016-2027)
Figure 39. China Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myelofibrosis Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Myelofibrosis Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Myelofibrosis Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myelofibrosis Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Myelofibrosis Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Myelofibrosis Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Myelofibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Incyte Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 59. Novartis Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 60. Celgene Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 61. Mylan Pharmaceuticals Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 63. Eli Lilly Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 64. Taro Pharmaceuticals Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 65. AllCells Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 66. Lonza Group Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 67. ATCC Revenue Growth Rate in Myelofibrosis Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
世界の慢性特発性骨髄線維症市場規模・現状・予測（2021年-2027年） Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively…- 世界の骨髄移植（BMT）市場規模・現状・予測（2021年-2027年） Bone marrow transplantation, also referred as hematopoietic stem cell transplantation is the process of replacing diseased or damaged bone marrow or bone marrow stem cells with healthy tissue. Bone marrow is a soft vascular tissue present in the interior of long bones, which is primarily responsible…
- 世界の転移性骨疾患治療市場規模・現状・予測（2021年-2027年） Metastatic bone disease treatments are treatment options of MBD which is a kind of cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone. Market Analysis and Insights: Global Metastatic Bone Disease Treatment Market The global Metastatic Bone Disease Treatm…
- 世界の骨痛治療市場規模・現状・予測（2021年-2027年） Bone pain is an ache in one or more bones in the body. The pain is generally connected to diseases that influence the normal function or structure of the bone. The major factor that drives the market is the increasing ageing population. There are various causes for bone pain disease such as Injury, …
- 世界の体外血液治療市場規模・現状・予測（2021年-2027年） The extracorporeal blood treatment is a type of filtration method used to remove many toxins from the blood. The demand for extracorporeal blood treatment is expected to upsurge owing to the growth of kidney diseases. Market Analysis and Insights: Global Extracorporeal Blood Treatment Market The glo…